文献速递炎症性肠病

系统综述与荟萃分析:炎症性肠病的诊断时间及延迟诊断对临床结局的影响

Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-10

该系统综述与荟萃分析检索EMBASE和Medline至2022年11月30日,纳入101项研究共112194例炎症性肠病(IBD)患者,计算诊断间隔并汇总延迟诊断对临床结局的比值比(OR)。结果显示克罗恩病(CD)中位诊断时间8.0个月、溃疡性结肠炎(UC)3.7个月,延迟诊断与CD狭窄、穿透性疾病及肠道手术风险升高相关,与UC结肠切除术风险升高相关。

要点

  • CD中位诊断时间8.0个月,UC为3.7个月,高收入国家短于中低收入国家。
  • 延迟诊断与CD狭窄(OR=1.88)、穿透性疾病(OR=1.64)及肠道手术(OR=2.24)风险升高相关。
  • 延迟诊断与UC结肠切除术风险升高相关(OR=4.13)。

核心结论

  • 延迟诊断与CD疾病进展相关,并与CD和UC的肠道手术相关。
  • 需要采取策略以实现IBD的早期诊断。

研究设计与样本

  • 系统综述与荟萃分析,检索EMBASE和Medline自建库至2022年11月30日。
  • 纳入101项报告从症状发作到IBD诊断的诊断间隔的研究,共112194例IBD患者(CD=59359;UC=52835)。
  • 延迟诊断定义为每项研究中诊断时间最长75百分位以上的个体。
  • 采用随机效应荟萃分析汇总报告临床结局研究的OR及95%CI。
  • 荟萃分析纳入11项研究共6164例患者(CD=4858;UC=1306)。

主要发现

  • CD中位诊断时间的中位数为8.0个月(IQR:5.0-15.2),UC为3.7个月(IQR:2.0-6.7)。
  • 高收入国家CD为6.2个月(IQR:5.0-12.3)、UC为3.2个月(IQR:2.2-5.3);中低收入国家CD为11.7个月(IQR:8.3-18.0)、UC为7.8个月(IQR:5.2-21.8)。
  • CD汇总加权中位数为7.0个月(95%CI:3.0-26.4),UC为4.6个月(95%CI:1.0-96.0)。
  • CD中延迟诊断与狭窄(OR=1.88;CI:1.35-2.62)、穿透性疾病(OR=1.64;CI:1.21-2.20)及肠道手术(OR=2.24;CI:1.57-3.19)风险升高相关。
  • UC中延迟诊断与结肠切除术风险升高相关(OR=4.13;CI:1.04-16.40)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of diagnostic delay on the clinical course of inflammatory bowel disease (IBD) remains uncertain. AIM: To perform a systematic review of time to diagnosis and the impact of delayed diagnosis on clinical outcomes in Crohn's disease (CD) and ulcerative colitis (UC). METHODS: We searched EMBASE and Medline from inception to 30th November 2022 for studies reporting diagnostic interval, from symptom onset to IBD diagnosis. We calculated the median, interquartile range (IQR) and pooled weighted median, of median diagnostic intervals of eligible studies. We defined delayed diagnosis as individuals above the 75th centile of longest time to diagnosis in each study. Using random effects meta-analysis, we pooled odds ratios (ORs) with 95% confidence intervals (CI) for studies reporting clinical outcomes, according to delayed diagnosis. RESULTS: One hundred and one studies representing 112,194 patients with IBD (CD = 59,359; UC = 52,835) met inclusion criteria. The median of median times to diagnosis was 8.0 (IQR: 5.0-15.2) and 3.7 months (IQR: 2.0-6.7) in CD and UC, respectively. In high-income countries, this was 6.2 (IQR: 5.0-12.3) and 3.2 months (IQR: 2.2-5.3), compared with 11.7 (IQR: 8.3-18.0) and 7.8 months (IQR: 5.2-21.8) in low-middle-income, countries, for CD and UC respectively. The pooled weighted median was 7.0 (95% CI: 3.0-26.4) and 4.6 (95% CI: 1.0-96.0) months, for CD and UC respectively. Eleven studies, representing 6164 patients (CD = 4858; UC = 1306), were included in the meta-analysis that examined the impact of diagnostic delay on clinical outcomes. In CD, delayed diagnosis was associated with higher odds of stricturing (OR = 1.88; CI: 1.35-2.62), penetrating disease (OR = 1.64; CI: 1.21-2.20) and intestinal surgery (OR = 2.24; CI: 1.57-3.19). In UC, delayed diagnosis was associated with higher odds of colectomy (OR = 4.13; CI: 1.04-16.40). CONCLUSION: Delayed diagnosis is associated with disease progression in CD, and intestinal surgery in both CD and UC. Strategies are needed to achieve earlier diagnosis of IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jayasooriya N, Baillie S, Blackwell J, et al. Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 36627691. doi:10.1111/apt.17370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。